Figure 7
Figure 7. GIFT15 and tumor xenotransplantation. (A-B) GIFT15 effect on U87GM xenotransplantation. Immunocompetent BALB/c mice (n = 6) were grafted with 107 live U87-GFP (□) or GIFT15 (▵) subcutaneously, and tumor volume as well as percentage survival were monitored over 8 months (P < .05 between the GIFT15 and GFP group). (C) Xenotransplantation of U87-GFP/GIFT15 in WT C57BL/6 or KO mice. Live U87-GFP or GIFT15 cells (107) were transplanted subcutaneously in WT C57BL/6 (n = 6/group), CD8−/− (n = 10/group), CD4−/− (n = 10/group), or beige (n = 10/group) mice, and graft survival was monitored over time (P < .05 between U87-GIFT15 and GFP). Results are shown as mean tumor volume ± SED.

GIFT15 and tumor xenotransplantation. (A-B) GIFT15 effect on U87GM xenotransplantation. Immunocompetent BALB/c mice (n = 6) were grafted with 107 live U87-GFP (□) or GIFT15 (▵) subcutaneously, and tumor volume as well as percentage survival were monitored over 8 months (P < .05 between the GIFT15 and GFP group). (C) Xenotransplantation of U87-GFP/GIFT15 in WT C57BL/6 or KO mice. Live U87-GFP or GIFT15 cells (107) were transplanted subcutaneously in WT C57BL/6 (n = 6/group), CD8−/− (n = 10/group), CD4−/− (n = 10/group), or beige (n = 10/group) mice, and graft survival was monitored over time (P < .05 between U87-GIFT15 and GFP). Results are shown as mean tumor volume ± SED.

Close Modal

or Create an Account

Close Modal
Close Modal